ArticleJournal of ginseng research2026
Korean red ginseng complex accelerates alcohol metabolism and relieves hangover symptoms in Humans: A randomized, double-blind, placebo-controlled crossover clinical trial.
Article in Journal of ginseng research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Alcohol hangovers are caused by delayed ethanol and acetaldehyde metabolism, leading to oxidative stress and physical discomfort. The Korean Red Ginseng Complex (KGC100FYK), composed of Korean red ginseng extract, fermented rice-soybean extract, and yeast extract, was developed to promote alcohol metabolism and relieve hangover symptoms. Methods: This randomized, double-blind, placebo-controlled, crossover clinical trial investigated the effects of KGC100FYK on alcohol metabolism and hangover-related symptoms in healthy adults. Participants received either KGC100FYK or placebo before alcohol ingestion (0.78 g/kg). Blood samples were obtained at baseline (0 h, before alcohol intake) and at 0.25, 0.5, 1, 2, 4, 6, and 15 h after alcohol intake to measure serum ethanol and acetaldehyde concentrations, and hangover symptoms were assessed using validated questionnaires. Results: KGC100FYK supplementation accelerated the initial reduction in serum ethanol concentrations and persistently attenuated acetaldehyde accumulation throughout the post-ingestion period relative to placebo. The area under the curve and maximum concentrations for both metabolites were decreased, indicating accelerated alcohol metabolism. Moreover, KGC100FYK alleviated subjective symptoms related to hangover at 6 and 15 h after alcohol consumption, resulting in lower total scores on both the Alcohol Hangover Scale and Alcohol Hangover Severity Scale. No adverse events or clinically relevant changes were observed in vital signs or biochemical parameters. Conclusion: These findings demonstrate that KGC100FYK safely accelerates ethanol and acetaldehyde clearance and alleviates hangover symptoms in healthy adults, supporting its effectiveness as a hangover-relief intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.